S1609, Dart: Dual Anti-CTLA-4 and Anti-PD-1 Blockage in Rare Tumors (CTMS# 17-0013)
To evaluate the RECIST 1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy.
To evaluate toxicities in each cohort.
To estimate overall survival (OS), progression-free survival (PFS), clinical benefit rate; and to estimate immune-related ORR (irORR), and immune-related PFS (irPFS) by unidimensional immune-related response criteria.
To collect specimens for banking for use in future correlative biomarker research studies.